患有无损功能患者的Cefepime诱导的脑病变:一个病例报告
Aayusha Dhakal1, Ozone Gautam2
1Department of Internal Medicine, Kathmandu University School of Medical Sciences, Dhulikhel, Nepal.
Case reports in infectious diseases
|April 7, 2025
概括
塞费皮姆抗生素可以引起神经毒性,即使在正常功能患者中也是如此. 这种罕见的病例凸显了对Cefepime诱导脑病变风险因素的进一步研究的需要.
科学领域:
- 神经科学是一个神经科学.
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 塞菲皮姆是第四代塞法洛斯波林,对于治疗耐药格兰氏阴性细菌感染至关重要,包括Pseudomonas aeruginosa.
- 它还适用于严重感染,败血症休克和免疫功能低下的患者.
- 塞费皮姆能够穿越血脑屏障,这可能导致神经毒性,主要在功能障碍患者中观察到.
研究的目的:
- 在患有正常功能的患者中报告一种罕见的Cefepime诱导的脑病变病例.
- 在这种情况下,要突出神经症状的不寻常表现.
- 强调需要进一步调查cefepime神经毒性风险因素的需要.
主要方法:
- 病例报告详细介绍患者的表现,临床过程和诊断过程.
- 排除其他潜在的脑病变原因.
- 观察患者对停止服用塞费皮姆的反应.
主要成果:
- 患者表现出混乱和不连贯,非典型的cefepime神经毒性在个人与完整的功能.
- 在排除其他原因后,诊断出Cefepime诱导的脑病变.
- 在停止塞费皮姆治疗后,神经症状消失.
结论:
- 塞费皮姆诱导的脑病变可能发生在正常功能患者中,挑战典型的临床表现.
- 这一案例强调了考虑塞费皮姆神经毒性的重要性,即使没有功能障碍.
- 需要进一步的研究来确定额外的危险因素,并了解塞费皮姆诱导的神经毒性的机制.
相关概念视频
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
272
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
272
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
196
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
196
01:20Antiepileptic Drugs: Potassium Channel Activators
134
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
134
01:17Factors Affecting Renal Clearance: Renal Impairment
36
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
36
01:11Renal Failure: Dose Adjustments
38
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
38
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
52
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
52